nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—CYP1B1—Progesterone—uterine cancer	0.107	0.181	CbGbCtD
Erlotinib—CYP1A1—Progesterone—uterine cancer	0.0472	0.0795	CbGbCtD
Erlotinib—UGT1A1—Etoposide—uterine cancer	0.0416	0.0701	CbGbCtD
Erlotinib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0411	0.0693	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—uterine cancer	0.0405	0.0683	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—uterine cancer	0.0328	0.0553	CbGbCtD
Erlotinib—CYP3A5—Progesterone—uterine cancer	0.0283	0.0477	CbGbCtD
Erlotinib—ABCG2—Carboplatin—uterine cancer	0.0272	0.0459	CbGbCtD
Erlotinib—CYP2C8—Progesterone—uterine cancer	0.0272	0.0459	CbGbCtD
Erlotinib—ABCG2—Etoposide—uterine cancer	0.0229	0.0386	CbGbCtD
Erlotinib—CYP1A2—Progesterone—uterine cancer	0.0211	0.0355	CbGbCtD
Erlotinib—ABCB1—Progesterone—uterine cancer	0.0184	0.0311	CbGbCtD
Erlotinib—CYP2D6—Progesterone—uterine cancer	0.0174	0.0293	CbGbCtD
Erlotinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0167	0.0281	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—uterine cancer	0.0156	0.0263	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—uterine cancer	0.0146	0.0246	CbGbCtD
Erlotinib—CYP3A5—Etoposide—uterine cancer	0.0127	0.0214	CbGbCtD
Erlotinib—CYP2C8—Etoposide—uterine cancer	0.0122	0.0205	CbGbCtD
Erlotinib—CYP3A4—Progesterone—uterine cancer	0.011	0.0186	CbGbCtD
Erlotinib—CYP1A2—Etoposide—uterine cancer	0.00943	0.0159	CbGbCtD
Erlotinib—ABCB1—Etoposide—uterine cancer	0.00824	0.0139	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—uterine cancer	0.00562	0.00948	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—uterine cancer	0.0053	0.00894	CbGbCtD
Erlotinib—CYP3A4—Etoposide—uterine cancer	0.00494	0.00833	CbGbCtD
Erlotinib—CYP3A4—Doxorubicin—uterine cancer	0.00337	0.00568	CbGbCtD
Erlotinib—Vandetanib—VEGFA—uterine cancer	0.00192	1	CrCbGaD
Erlotinib—HIPK4—female reproductive system—uterine cancer	0.00173	0.0152	CbGeAlD
Erlotinib—LTK—female reproductive system—uterine cancer	0.00171	0.015	CbGeAlD
Erlotinib—TNK1—uterine cervix—uterine cancer	0.00167	0.0147	CbGeAlD
Erlotinib—PIP4K2C—myometrium—uterine cancer	0.00167	0.0147	CbGeAlD
Erlotinib—TNK1—decidua—uterine cancer	0.00159	0.014	CbGeAlD
Erlotinib—ULK3—myometrium—uterine cancer	0.00159	0.014	CbGeAlD
Erlotinib—TNK1—endometrium—uterine cancer	0.00151	0.0133	CbGeAlD
Erlotinib—MKNK1—myometrium—uterine cancer	0.0015	0.0132	CbGeAlD
Erlotinib—AURKC—female reproductive system—uterine cancer	0.00147	0.013	CbGeAlD
Erlotinib—TNK1—mammalian vulva—uterine cancer	0.00146	0.0129	CbGeAlD
Erlotinib—SLK—myometrium—uterine cancer	0.00142	0.0125	CbGeAlD
Erlotinib—TNK1—uterus—uterine cancer	0.00139	0.0123	CbGeAlD
Erlotinib—EPHA6—female reproductive system—uterine cancer	0.00137	0.012	CbGeAlD
Erlotinib—JAK3—female reproductive system—uterine cancer	0.00137	0.012	CbGeAlD
Erlotinib—EGFR—uterine cervix—uterine cancer	0.00134	0.0118	CbGeAlD
Erlotinib—PIP4K2C—uterine cervix—uterine cancer	0.0013	0.0114	CbGeAlD
Erlotinib—JAK3—female gonad—uterine cancer	0.00124	0.0109	CbGeAlD
Erlotinib—MAP3K19—female reproductive system—uterine cancer	0.00124	0.0109	CbGeAlD
Erlotinib—ULK3—uterine cervix—uterine cancer	0.00124	0.0109	CbGeAlD
Erlotinib—PIP4K2C—decidua—uterine cancer	0.00124	0.0109	CbGeAlD
Erlotinib—STK10—myometrium—uterine cancer	0.00124	0.0109	CbGeAlD
Erlotinib—ULK3—decidua—uterine cancer	0.00118	0.0104	CbGeAlD
Erlotinib—PIP4K2C—endometrium—uterine cancer	0.00117	0.0103	CbGeAlD
Erlotinib—EGFR—mammalian vulva—uterine cancer	0.00117	0.0103	CbGeAlD
Erlotinib—MKNK1—uterine cervix—uterine cancer	0.00117	0.0103	CbGeAlD
Erlotinib—TNK1—female gonad—uterine cancer	0.00114	0.01	CbGeAlD
Erlotinib—PIP4K2C—mammalian vulva—uterine cancer	0.00114	0.00999	CbGeAlD
Erlotinib—TNK1—vagina—uterine cancer	0.00113	0.00997	CbGeAlD
Erlotinib—ULK3—endometrium—uterine cancer	0.00112	0.00986	CbGeAlD
Erlotinib—EGFR—uterus—uterine cancer	0.00112	0.00981	CbGeAlD
Erlotinib—MKNK1—decidua—uterine cancer	0.00111	0.00977	CbGeAlD
Erlotinib—SLK—uterine cervix—uterine cancer	0.00111	0.00971	CbGeAlD
Erlotinib—MAP2K5—myometrium—uterine cancer	0.0011	0.00969	CbGeAlD
Erlotinib—ULK3—mammalian vulva—uterine cancer	0.00109	0.00954	CbGeAlD
Erlotinib—FLT3—female reproductive system—uterine cancer	0.00108	0.00947	CbGeAlD
Erlotinib—MKNK1—endometrium—uterine cancer	0.00106	0.00928	CbGeAlD
Erlotinib—SLK—decidua—uterine cancer	0.00105	0.00926	CbGeAlD
Erlotinib—ULK3—uterus—uterine cancer	0.00103	0.00908	CbGeAlD
Erlotinib—MKNK1—mammalian vulva—uterine cancer	0.00102	0.00897	CbGeAlD
Erlotinib—SLK—endometrium—uterine cancer	0.001	0.00879	CbGeAlD
Erlotinib—LTK—lymph node—uterine cancer	0.000999	0.00878	CbGeAlD
Erlotinib—FLT3—female gonad—uterine cancer	0.00098	0.00861	CbGeAlD
Erlotinib—PIP4K2C—female reproductive system—uterine cancer	0.000973	0.00855	CbGeAlD
Erlotinib—SLK—mammalian vulva—uterine cancer	0.000967	0.0085	CbGeAlD
Erlotinib—STK10—uterine cervix—uterine cancer	0.000961	0.00845	CbGeAlD
Erlotinib—ABL2—female gonad—uterine cancer	0.000936	0.00822	CbGeAlD
Erlotinib—ABL2—vagina—uterine cancer	0.00093	0.00817	CbGeAlD
Erlotinib—ULK3—female reproductive system—uterine cancer	0.000929	0.00817	CbGeAlD
Erlotinib—SLK—uterus—uterine cancer	0.000921	0.0081	CbGeAlD
Erlotinib—STK10—decidua—uterine cancer	0.000916	0.00805	CbGeAlD
Erlotinib—EGFR—female gonad—uterine cancer	0.000914	0.00803	CbGeAlD
Erlotinib—STK10—renal system—uterine cancer	0.000899	0.0079	CbGeAlD
Erlotinib—PIP4K2C—female gonad—uterine cancer	0.000886	0.00778	CbGeAlD
Erlotinib—PIP4K2C—vagina—uterine cancer	0.00088	0.00773	CbGeAlD
Erlotinib—MKNK1—female reproductive system—uterine cancer	0.000875	0.00769	CbGeAlD
Erlotinib—AURKC—lymph node—uterine cancer	0.000863	0.00758	CbGeAlD
Erlotinib—MAP2K5—uterine cervix—uterine cancer	0.000858	0.00754	CbGeAlD
Erlotinib—ABL1—myometrium—uterine cancer	0.000851	0.00748	CbGeAlD
Erlotinib—UGT1A1—renal system—uterine cancer	0.000849	0.00746	CbGeAlD
Erlotinib—ULK3—female gonad—uterine cancer	0.000846	0.00743	CbGeAlD
Erlotinib—STK10—mammalian vulva—uterine cancer	0.000841	0.00739	CbGeAlD
Erlotinib—ULK3—vagina—uterine cancer	0.00084	0.00739	CbGeAlD
Erlotinib—MAP2K5—decidua—uterine cancer	0.000818	0.00719	CbGeAlD
Erlotinib—STK10—uterus—uterine cancer	0.000801	0.00704	CbGeAlD
Erlotinib—JAK3—lymph node—uterine cancer	0.000799	0.00702	CbGeAlD
Erlotinib—MKNK1—female gonad—uterine cancer	0.000796	0.00699	CbGeAlD
Erlotinib—MKNK1—vagina—uterine cancer	0.000791	0.00695	CbGeAlD
Erlotinib—MAP2K5—endometrium—uterine cancer	0.000776	0.00682	CbGeAlD
Erlotinib—SLK—female gonad—uterine cancer	0.000754	0.00662	CbGeAlD
Erlotinib—MAP2K5—mammalian vulva—uterine cancer	0.000751	0.0066	CbGeAlD
Erlotinib—SLK—vagina—uterine cancer	0.000749	0.00658	CbGeAlD
Erlotinib—TNK1—lymph node—uterine cancer	0.000734	0.00645	CbGeAlD
Erlotinib—STK10—female reproductive system—uterine cancer	0.00072	0.00633	CbGeAlD
Erlotinib—ABL1—uterine cervix—uterine cancer	0.000662	0.00582	CbGeAlD
Erlotinib—STK10—female gonad—uterine cancer	0.000655	0.00576	CbGeAlD
Erlotinib—STK10—vagina—uterine cancer	0.000651	0.00572	CbGeAlD
Erlotinib—ABL1—smooth muscle tissue—uterine cancer	0.000644	0.00566	CbGeAlD
Erlotinib—MAP2K5—female reproductive system—uterine cancer	0.000643	0.00565	CbGeAlD
Erlotinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000639	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000639	0.173	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000639	0.173	CbGdCrCtD
Erlotinib—SLCO2B1—decidua—uterine cancer	0.000636	0.00559	CbGeAlD
Erlotinib—ABL1—decidua—uterine cancer	0.000631	0.00554	CbGeAlD
Erlotinib—ORM1—endometrium—uterine cancer	0.00063	0.00554	CbGeAlD
Erlotinib—FLT3—lymph node—uterine cancer	0.00063	0.00554	CbGeAlD
Erlotinib—SLCO2B1—renal system—uterine cancer	0.000625	0.00549	CbGeAlD
Erlotinib—ABL1—renal system—uterine cancer	0.00062	0.00544	CbGeAlD
Erlotinib—ABL2—lymph node—uterine cancer	0.000602	0.00529	CbGeAlD
Erlotinib—ABL1—endometrium—uterine cancer	0.000599	0.00526	CbGeAlD
Erlotinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000591	0.16	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000591	0.16	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000591	0.16	CbGdCrCtD
Erlotinib—EGFR—lymph node—uterine cancer	0.000587	0.00516	CbGeAlD
Erlotinib—MAP2K5—female gonad—uterine cancer	0.000585	0.00514	CbGeAlD
Erlotinib—MAP2K5—vagina—uterine cancer	0.000582	0.00511	CbGeAlD
Erlotinib—ABL1—mammalian vulva—uterine cancer	0.000579	0.00509	CbGeAlD
Erlotinib—PIP4K2C—lymph node—uterine cancer	0.000569	0.005	CbGeAlD
Erlotinib—SLCO2B1—uterus—uterine cancer	0.000557	0.00489	CbGeAlD
Erlotinib—ABL1—uterus—uterine cancer	0.000552	0.00485	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—uterine cancer	0.000545	0.00479	CbGeAlD
Erlotinib—ULK3—lymph node—uterine cancer	0.000544	0.00478	CbGeAlD
Erlotinib—ABCG2—myometrium—uterine cancer	0.000537	0.00472	CbGeAlD
Erlotinib—CYP1B1—decidua—uterine cancer	0.000534	0.0047	CbGeAlD
Erlotinib—CYP1B1—renal system—uterine cancer	0.000525	0.00461	CbGeAlD
Erlotinib—ORM1—female reproductive system—uterine cancer	0.000522	0.00459	CbGeAlD
Erlotinib—MKNK1—lymph node—uterine cancer	0.000512	0.0045	CbGeAlD
Erlotinib—SLCO2B1—female reproductive system—uterine cancer	0.000501	0.0044	CbGeAlD
Erlotinib—ABL1—female reproductive system—uterine cancer	0.000496	0.00436	CbGeAlD
Erlotinib—SLK—lymph node—uterine cancer	0.000485	0.00426	CbGeAlD
Erlotinib—CYP1B1—uterus—uterine cancer	0.000467	0.00411	CbGeAlD
Erlotinib—SLCO2B1—female gonad—uterine cancer	0.000455	0.004	CbGeAlD
Erlotinib—ABL1—female gonad—uterine cancer	0.000452	0.00397	CbGeAlD
Erlotinib—ABL1—vagina—uterine cancer	0.000449	0.00394	CbGeAlD
Erlotinib—STK10—lymph node—uterine cancer	0.000421	0.0037	CbGeAlD
Erlotinib—CYP1B1—female reproductive system—uterine cancer	0.00042	0.00369	CbGeAlD
Erlotinib—ABCG2—uterine cervix—uterine cancer	0.000418	0.00367	CbGeAlD
Erlotinib—CYP2C8—renal system—uterine cancer	0.000402	0.00353	CbGeAlD
Erlotinib—CYP1A1—epithelium—uterine cancer	0.0004	0.00351	CbGeAlD
Erlotinib—ABCG2—decidua—uterine cancer	0.000398	0.0035	CbGeAlD
Erlotinib—CYP1A1—uterine cervix—uterine cancer	0.000396	0.00348	CbGeAlD
Erlotinib—CYP2C8—endometrium—uterine cancer	0.000388	0.00341	CbGeAlD
Erlotinib—CYP3A5—uterine cervix—uterine cancer	0.000388	0.00341	CbGeAlD
Erlotinib—CYP1B1—female gonad—uterine cancer	0.000382	0.00336	CbGeAlD
Erlotinib—ABCG2—endometrium—uterine cancer	0.000378	0.00332	CbGeAlD
Erlotinib—MAP2K5—lymph node—uterine cancer	0.000376	0.00331	CbGeAlD
Erlotinib—CYP1A2—renal system—uterine cancer	0.000376	0.0033	CbGeAlD
Erlotinib—CYP1A1—renal system—uterine cancer	0.000371	0.00326	CbGeAlD
Erlotinib—ABCG2—mammalian vulva—uterine cancer	0.000365	0.00321	CbGeAlD
Erlotinib—CYP3A5—renal system—uterine cancer	0.000363	0.00319	CbGeAlD
Erlotinib—ABCG2—uterus—uterine cancer	0.000348	0.00306	CbGeAlD
Erlotinib—CYP1A1—mammalian vulva—uterine cancer	0.000347	0.00305	CbGeAlD
Erlotinib—CYP1A1—uterus—uterine cancer	0.00033	0.0029	CbGeAlD
Erlotinib—CYP2C8—female reproductive system—uterine cancer	0.000322	0.00283	CbGeAlD
Erlotinib—ORM1—lymph node—uterine cancer	0.000305	0.00268	CbGeAlD
Erlotinib—CYP1A1—female reproductive system—uterine cancer	0.000297	0.00261	CbGeAlD
Erlotinib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000295	0.00181	CcSEcCtD
Erlotinib—Stomatitis—Etoposide—uterine cancer	0.000295	0.00181	CcSEcCtD
Erlotinib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000294	0.00181	CcSEcCtD
Erlotinib—SLCO2B1—lymph node—uterine cancer	0.000293	0.00257	CbGeAlD
Erlotinib—Bone pain—Doxorubicin—uterine cancer	0.000293	0.0018	CcSEcCtD
Erlotinib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000292	0.00179	CcSEcCtD
Erlotinib—CYP2C8—vagina—uterine cancer	0.000291	0.00256	CbGeAlD
Erlotinib—Colitis—Epirubicin—uterine cancer	0.000291	0.00178	CcSEcCtD
Erlotinib—ABL1—lymph node—uterine cancer	0.00029	0.00255	CbGeAlD
Erlotinib—Skin exfoliation—Epirubicin—uterine cancer	0.000289	0.00177	CcSEcCtD
Erlotinib—Inflammation—Doxorubicin—uterine cancer	0.000289	0.00177	CcSEcCtD
Erlotinib—Hepatobiliary disease—Etoposide—uterine cancer	0.000286	0.00175	CcSEcCtD
Erlotinib—ABCG2—female gonad—uterine cancer	0.000285	0.0025	CbGeAlD
Erlotinib—Neuropathy—Epirubicin—uterine cancer	0.000284	0.00175	CcSEcCtD
Erlotinib—Musculoskeletal pain—Doxorubicin—uterine cancer	0.000284	0.00174	CcSEcCtD
Erlotinib—ABCG2—vagina—uterine cancer	0.000283	0.00249	CbGeAlD
Erlotinib—Hepatocellular injury—Doxorubicin—uterine cancer	0.00028	0.00172	CcSEcCtD
Erlotinib—Dry eye—Epirubicin—uterine cancer	0.00028	0.00172	CcSEcCtD
Erlotinib—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000279	0.00171	CcSEcCtD
Erlotinib—Myalgia—Dactinomycin—uterine cancer	0.000278	0.00171	CcSEcCtD
Erlotinib—Melaena—Doxorubicin—uterine cancer	0.000274	0.00168	CcSEcCtD
Erlotinib—CYP3A4—renal system—uterine cancer	0.000272	0.00239	CbGeAlD
Erlotinib—Asthenia—Progesterone—uterine cancer	0.00027	0.00166	CcSEcCtD
Erlotinib—CYP1A1—female gonad—uterine cancer	0.00027	0.00238	CbGeAlD
Erlotinib—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00027	0.00166	CcSEcCtD
Erlotinib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00027	0.00166	CcSEcCtD
Erlotinib—Colitis—Doxorubicin—uterine cancer	0.000269	0.00165	CcSEcCtD
Erlotinib—CYP1A1—vagina—uterine cancer	0.000269	0.00236	CbGeAlD
Erlotinib—Urinary tract disorder—Etoposide—uterine cancer	0.000268	0.00164	CcSEcCtD
Erlotinib—ALB—lymph node—uterine cancer	0.000268	0.00235	CbGeAlD
Erlotinib—CYP2D6—renal system—uterine cancer	0.000268	0.00235	CbGeAlD
Erlotinib—Skin exfoliation—Doxorubicin—uterine cancer	0.000268	0.00164	CcSEcCtD
Erlotinib—Pruritus—Progesterone—uterine cancer	0.000267	0.00164	CcSEcCtD
Erlotinib—Oedema—Dactinomycin—uterine cancer	0.000266	0.00163	CcSEcCtD
Erlotinib—Urethral disorder—Etoposide—uterine cancer	0.000266	0.00163	CcSEcCtD
Erlotinib—Infection—Dactinomycin—uterine cancer	0.000265	0.00162	CcSEcCtD
Erlotinib—ABCB1—myometrium—uterine cancer	0.000265	0.00233	CbGeAlD
Erlotinib—CYP3A5—female gonad—uterine cancer	0.000264	0.00232	CbGeAlD
Erlotinib—Neuropathy—Doxorubicin—uterine cancer	0.000263	0.00161	CcSEcCtD
Erlotinib—Sepsis—Epirubicin—uterine cancer	0.000263	0.00161	CcSEcCtD
Erlotinib—CYP3A5—vagina—uterine cancer	0.000263	0.00231	CbGeAlD
Erlotinib—Thrombocytopenia—Dactinomycin—uterine cancer	0.000261	0.0016	CcSEcCtD
Erlotinib—Dry eye—Doxorubicin—uterine cancer	0.000259	0.00159	CcSEcCtD
Erlotinib—Diarrhoea—Progesterone—uterine cancer	0.000258	0.00158	CcSEcCtD
Erlotinib—Erythema multiforme—Etoposide—uterine cancer	0.000257	0.00157	CcSEcCtD
Erlotinib—Anorexia—Dactinomycin—uterine cancer	0.000254	0.00156	CcSEcCtD
Erlotinib—Eye disorder—Etoposide—uterine cancer	0.000254	0.00156	CcSEcCtD
Erlotinib—Dizziness—Progesterone—uterine cancer	0.000249	0.00153	CcSEcCtD
Erlotinib—CYP1B1—lymph node—uterine cancer	0.000246	0.00216	CbGeAlD
Erlotinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000245	0.0015	CcSEcCtD
Erlotinib—Hepatic failure—Epirubicin—uterine cancer	0.000245	0.0015	CcSEcCtD
Erlotinib—Mediastinal disorder—Etoposide—uterine cancer	0.000245	0.0015	CcSEcCtD
Erlotinib—Chills—Etoposide—uterine cancer	0.000244	0.00149	CcSEcCtD
Erlotinib—Sepsis—Doxorubicin—uterine cancer	0.000243	0.00149	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000243	0.00149	CcSEcCtD
Erlotinib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000242	0.00148	CcSEcCtD
Erlotinib—Alopecia—Etoposide—uterine cancer	0.00024	0.00147	CcSEcCtD
Erlotinib—Vomiting—Progesterone—uterine cancer	0.00024	0.00147	CcSEcCtD
Erlotinib—Renal failure acute—Epirubicin—uterine cancer	0.000238	0.00146	CcSEcCtD
Erlotinib—Rash—Progesterone—uterine cancer	0.000238	0.00146	CcSEcCtD
Erlotinib—Dermatitis—Progesterone—uterine cancer	0.000237	0.00146	CcSEcCtD
Erlotinib—Headache—Progesterone—uterine cancer	0.000236	0.00145	CcSEcCtD
Erlotinib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000234	0.00143	CcSEcCtD
Erlotinib—Decreased appetite—Dactinomycin—uterine cancer	0.000232	0.00142	CcSEcCtD
Erlotinib—Renal impairment—Epirubicin—uterine cancer	0.000231	0.00142	CcSEcCtD
Erlotinib—Dermatitis bullous—Epirubicin—uterine cancer	0.00023	0.00141	CcSEcCtD
Erlotinib—Fatigue—Dactinomycin—uterine cancer	0.00023	0.00141	CcSEcCtD
Erlotinib—Back pain—Etoposide—uterine cancer	0.000229	0.0014	CcSEcCtD
Erlotinib—Pain—Dactinomycin—uterine cancer	0.000228	0.0014	CcSEcCtD
Erlotinib—Hepatic failure—Doxorubicin—uterine cancer	0.000226	0.00139	CcSEcCtD
Erlotinib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000226	0.00139	CcSEcCtD
Erlotinib—Cerebrovascular accident—Epirubicin—uterine cancer	0.000224	0.00138	CcSEcCtD
Erlotinib—Nausea—Progesterone—uterine cancer	0.000224	0.00137	CcSEcCtD
Erlotinib—Renal failure acute—Doxorubicin—uterine cancer	0.00022	0.00135	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.00022	0.00135	CcSEcCtD
Erlotinib—CYP3A4—female reproductive system—uterine cancer	0.000218	0.00192	CbGeAlD
Erlotinib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000218	0.00134	CcSEcCtD
Erlotinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000217	0.00133	CcSEcCtD
Erlotinib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000215	0.00132	CcSEcCtD
Erlotinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000215	0.00132	CcSEcCtD
Erlotinib—CYP2D6—female reproductive system—uterine cancer	0.000215	0.00188	CbGeAlD
Erlotinib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000214	0.00131	CcSEcCtD
Erlotinib—Renal impairment—Doxorubicin—uterine cancer	0.000214	0.00131	CcSEcCtD
Erlotinib—Dermatitis bullous—Doxorubicin—uterine cancer	0.000213	0.00131	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—uterine cancer	0.000211	0.00129	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—uterine cancer	0.000211	0.00129	CcSEcCtD
Erlotinib—ABCB1—epithelium—uterine cancer	0.000208	0.00183	CbGeAlD
Erlotinib—Loss of consciousness—Etoposide—uterine cancer	0.000208	0.00127	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000208	0.00127	CcSEcCtD
Erlotinib—Cough—Etoposide—uterine cancer	0.000206	0.00126	CcSEcCtD
Erlotinib—ABCB1—uterine cervix—uterine cancer	0.000206	0.00181	CbGeAlD
Erlotinib—Dehydration—Epirubicin—uterine cancer	0.000205	0.00125	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000203	0.00125	CcSEcCtD
Erlotinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000203	0.00124	CcSEcCtD
Erlotinib—Dry skin—Epirubicin—uterine cancer	0.000202	0.00124	CcSEcCtD
Erlotinib—Chest pain—Etoposide—uterine cancer	0.000201	0.00123	CcSEcCtD
Erlotinib—Hypokalaemia—Epirubicin—uterine cancer	0.0002	0.00123	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.0002	0.00123	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000198	0.00122	CcSEcCtD
Erlotinib—ABCB1—decidua—uterine cancer	0.000196	0.00172	CbGeAlD
Erlotinib—CYP2D6—female gonad—uterine cancer	0.000195	0.00172	CbGeAlD
Erlotinib—Gastritis—Epirubicin—uterine cancer	0.000195	0.00119	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000194	0.00119	CcSEcCtD
Erlotinib—ABCB1—renal system—uterine cancer	0.000193	0.00169	CbGeAlD
Erlotinib—Infection—Etoposide—uterine cancer	0.000192	0.00118	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—uterine cancer	0.000191	0.00117	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—uterine cancer	0.00019	0.00117	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—uterine cancer	0.000189	0.00116	CcSEcCtD
Erlotinib—Thrombocytopenia—Etoposide—uterine cancer	0.000189	0.00116	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—uterine cancer	0.000187	0.00115	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—uterine cancer	0.000187	0.00114	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—uterine cancer	0.000186	0.00114	CcSEcCtD
Erlotinib—ABCB1—endometrium—uterine cancer	0.000186	0.00164	CbGeAlD
Erlotinib—Hypokalaemia—Doxorubicin—uterine cancer	0.000185	0.00114	CcSEcCtD
Erlotinib—Anorexia—Etoposide—uterine cancer	0.000184	0.00113	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000183	0.00112	CcSEcCtD
Erlotinib—ABCG2—lymph node—uterine cancer	0.000183	0.00161	CbGeAlD
Erlotinib—Diarrhoea—Dactinomycin—uterine cancer	0.000182	0.00112	CcSEcCtD
Erlotinib—ABCB1—mammalian vulva—uterine cancer	0.00018	0.00158	CbGeAlD
Erlotinib—Gastritis—Doxorubicin—uterine cancer	0.00018	0.0011	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000179	0.0011	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—uterine cancer	0.000178	0.00109	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—uterine cancer	0.000176	0.00108	CcSEcCtD
Erlotinib—CYP1A1—lymph node—uterine cancer	0.000174	0.00153	CbGeAlD
Erlotinib—Pancreatitis—Doxorubicin—uterine cancer	0.000172	0.00106	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—uterine cancer	0.000172	0.00106	CcSEcCtD
Erlotinib—Dyspnoea—Etoposide—uterine cancer	0.000172	0.00105	CcSEcCtD
Erlotinib—ABCB1—uterus—uterine cancer	0.000172	0.00151	CbGeAlD
Erlotinib—Pneumonia—Epirubicin—uterine cancer	0.00017	0.00105	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—uterine cancer	0.000169	0.00104	CcSEcCtD
Erlotinib—Infestation—Epirubicin—uterine cancer	0.000169	0.00104	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—uterine cancer	0.000169	0.00104	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000168	0.00103	CcSEcCtD
Erlotinib—Rash—Dactinomycin—uterine cancer	0.000168	0.00103	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—uterine cancer	0.000168	0.00103	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—uterine cancer	0.000167	0.00102	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000166	0.00102	CcSEcCtD
Erlotinib—Fatigue—Etoposide—uterine cancer	0.000166	0.00102	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—uterine cancer	0.000166	0.00102	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—uterine cancer	0.000165	0.00101	CcSEcCtD
Erlotinib—Constipation—Etoposide—uterine cancer	0.000165	0.00101	CcSEcCtD
Erlotinib—Pain—Etoposide—uterine cancer	0.000165	0.00101	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—uterine cancer	0.000165	0.00101	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—uterine cancer	0.000164	0.00101	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—uterine cancer	0.00016	0.000983	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—uterine cancer	0.00016	0.000981	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—uterine cancer	0.000159	0.000976	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—uterine cancer	0.000158	0.000971	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—uterine cancer	0.000158	0.000968	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—uterine cancer	0.000158	0.000967	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—uterine cancer	0.000157	0.000962	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—uterine cancer	0.000157	0.000962	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000155	0.000954	CcSEcCtD
Erlotinib—ABCB1—female reproductive system—uterine cancer	0.000154	0.00136	CbGeAlD
Erlotinib—Renal failure—Doxorubicin—uterine cancer	0.000154	0.000946	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000154	0.000943	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—uterine cancer	0.000153	0.000938	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—uterine cancer	0.000153	0.000938	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—uterine cancer	0.000152	0.000935	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—uterine cancer	0.000152	0.000935	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—uterine cancer	0.000152	0.000935	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—uterine cancer	0.000152	0.000933	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—uterine cancer	0.000152	0.000933	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—uterine cancer	0.00015	0.000922	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—uterine cancer	0.000149	0.000917	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—uterine cancer	0.000149	0.000915	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000148	0.00091	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—uterine cancer	0.000148	0.000907	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—uterine cancer	0.000144	0.000883	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—uterine cancer	0.000142	0.000872	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—uterine cancer	0.000141	0.000868	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—uterine cancer	0.000141	0.000864	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—uterine cancer	0.000141	0.000864	CcSEcCtD
Erlotinib—ABCB1—female gonad—uterine cancer	0.00014	0.00123	CbGeAlD
Erlotinib—ABCB1—vagina—uterine cancer	0.00014	0.00123	CbGeAlD
Erlotinib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000139	0.000853	CcSEcCtD
Erlotinib—Asthenia—Etoposide—uterine cancer	0.000138	0.000849	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—uterine cancer	0.000138	0.000849	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—uterine cancer	0.000138	0.000847	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—uterine cancer	0.000137	0.000841	CcSEcCtD
Erlotinib—Chills—Epirubicin—uterine cancer	0.000137	0.000838	CcSEcCtD
Erlotinib—Pruritus—Etoposide—uterine cancer	0.000136	0.000837	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—uterine cancer	0.000136	0.000834	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—uterine cancer	0.000134	0.000825	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—uterine cancer	0.000133	0.000818	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—uterine cancer	0.000133	0.000817	CcSEcCtD
Erlotinib—Erythema—Epirubicin—uterine cancer	0.000132	0.000813	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—uterine cancer	0.000132	0.000813	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—uterine cancer	0.000132	0.000809	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—uterine cancer	0.000132	0.000807	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—uterine cancer	0.00013	0.000801	CcSEcCtD
Erlotinib—Back pain—Epirubicin—uterine cancer	0.000128	0.000786	CcSEcCtD
Erlotinib—Dizziness—Etoposide—uterine cancer	0.000128	0.000782	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—uterine cancer	0.000127	0.000778	CcSEcCtD
Erlotinib—Chills—Doxorubicin—uterine cancer	0.000126	0.000775	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—uterine cancer	0.000126	0.000772	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—uterine cancer	0.000124	0.000763	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—uterine cancer	0.000123	0.000757	CcSEcCtD
Erlotinib—Vomiting—Etoposide—uterine cancer	0.000123	0.000752	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—uterine cancer	0.000123	0.000752	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—uterine cancer	0.000123	0.000752	CcSEcCtD
Erlotinib—Rash—Etoposide—uterine cancer	0.000122	0.000746	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—uterine cancer	0.000121	0.000745	CcSEcCtD
Erlotinib—Headache—Etoposide—uterine cancer	0.000121	0.000741	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—uterine cancer	0.000121	0.000741	CcSEcCtD
Erlotinib—Syncope—Epirubicin—uterine cancer	0.000119	0.000729	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—uterine cancer	0.000119	0.000727	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—uterine cancer	0.000116	0.000714	CcSEcCtD
Erlotinib—Cough—Epirubicin—uterine cancer	0.000116	0.000709	CcSEcCtD
Erlotinib—Nausea—Etoposide—uterine cancer	0.000115	0.000703	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—uterine cancer	0.000113	0.000692	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—uterine cancer	0.000113	0.000692	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—uterine cancer	0.000113	0.000692	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—uterine cancer	0.000112	0.000689	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000112	0.000687	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—uterine cancer	0.00011	0.000674	CcSEcCtD
Erlotinib—Oedema—Epirubicin—uterine cancer	0.000108	0.000663	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—uterine cancer	0.000108	0.000661	CcSEcCtD
Erlotinib—Infection—Epirubicin—uterine cancer	0.000107	0.000659	CcSEcCtD
Erlotinib—Cough—Doxorubicin—uterine cancer	0.000107	0.000656	CcSEcCtD
Erlotinib—Shock—Epirubicin—uterine cancer	0.000106	0.000652	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—uterine cancer	0.000106	0.00065	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—uterine cancer	0.000106	0.000649	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—uterine cancer	0.000105	0.000644	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—uterine cancer	0.000104	0.00064	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—uterine cancer	0.000104	0.00064	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—uterine cancer	0.000104	0.00064	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—uterine cancer	0.000104	0.000638	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000104	0.000636	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—uterine cancer	0.000103	0.000632	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—uterine cancer	0.0001	0.000614	CcSEcCtD
Erlotinib—Infection—Doxorubicin—uterine cancer	9.94e-05	0.00061	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	9.85e-05	0.000604	CcSEcCtD
Erlotinib—Shock—Doxorubicin—uterine cancer	9.84e-05	0.000604	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—uterine cancer	9.81e-05	0.000602	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—uterine cancer	9.79e-05	0.000601	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—uterine cancer	9.78e-05	0.0006	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—uterine cancer	9.71e-05	0.000596	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—uterine cancer	9.64e-05	0.000591	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—uterine cancer	9.53e-05	0.000585	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—uterine cancer	9.51e-05	0.000584	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—uterine cancer	9.4e-05	0.000576	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—uterine cancer	9.33e-05	0.000573	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—uterine cancer	9.32e-05	0.000572	CcSEcCtD
Erlotinib—Constipation—Epirubicin—uterine cancer	9.24e-05	0.000567	CcSEcCtD
Erlotinib—Pain—Epirubicin—uterine cancer	9.24e-05	0.000567	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	9.11e-05	0.000559	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—uterine cancer	9.05e-05	0.000555	CcSEcCtD
Erlotinib—ABCB1—lymph node—uterine cancer	9.03e-05	0.000793	CbGeAlD
Erlotinib—Dyspnoea—Doxorubicin—uterine cancer	8.92e-05	0.000547	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—uterine cancer	8.84e-05	0.000542	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—uterine cancer	8.8e-05	0.00054	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—uterine cancer	8.69e-05	0.000533	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	8.63e-05	0.00053	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—uterine cancer	8.62e-05	0.000529	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—uterine cancer	8.55e-05	0.000525	CcSEcCtD
Erlotinib—Pain—Doxorubicin—uterine cancer	8.55e-05	0.000525	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—uterine cancer	8.54e-05	0.000524	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—uterine cancer	8.54e-05	0.000524	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—uterine cancer	8.18e-05	0.000502	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—uterine cancer	7.91e-05	0.000485	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—uterine cancer	7.91e-05	0.000485	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—uterine cancer	7.75e-05	0.000476	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—uterine cancer	7.65e-05	0.000469	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—uterine cancer	7.4e-05	0.000454	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—uterine cancer	7.18e-05	0.00044	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—uterine cancer	7.15e-05	0.000439	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—uterine cancer	7.08e-05	0.000434	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—uterine cancer	6.87e-05	0.000422	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—uterine cancer	6.84e-05	0.00042	CcSEcCtD
Erlotinib—Rash—Epirubicin—uterine cancer	6.81e-05	0.000418	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—uterine cancer	6.81e-05	0.000418	CcSEcCtD
Erlotinib—Headache—Epirubicin—uterine cancer	6.77e-05	0.000415	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—uterine cancer	6.61e-05	0.000406	CcSEcCtD
Erlotinib—Nausea—Epirubicin—uterine cancer	6.42e-05	0.000394	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—uterine cancer	6.36e-05	0.00039	CcSEcCtD
Erlotinib—Rash—Doxorubicin—uterine cancer	6.31e-05	0.000387	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—uterine cancer	6.3e-05	0.000387	CcSEcCtD
Erlotinib—Headache—Doxorubicin—uterine cancer	6.27e-05	0.000384	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—uterine cancer	5.94e-05	0.000364	CcSEcCtD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.15e-05	9.26e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CDKN1B—uterine cancer	1.15e-05	9.22e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—RRM2—uterine cancer	1.14e-05	9.15e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP11A1—uterine cancer	1.14e-05	9.13e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKR1C3—uterine cancer	1.14e-05	9.12e-05	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AKT1—uterine cancer	1.14e-05	9.12e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—RRM2—uterine cancer	1.13e-05	9.1e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PIK3CA—uterine cancer	1.13e-05	9.04e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POLD1—uterine cancer	1.12e-05	9.01e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKR1C1—uterine cancer	1.12e-05	8.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STK11—uterine cancer	1.11e-05	8.88e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—DCN—uterine cancer	1.11e-05	8.88e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KRAS—uterine cancer	1.11e-05	8.86e-05	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AKT1—uterine cancer	1.1e-05	8.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL2—uterine cancer	1.1e-05	8.84e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—DCN—uterine cancer	1.1e-05	8.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—uterine cancer	1.1e-05	8.8e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTHFR—uterine cancer	1.1e-05	8.78e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—uterine cancer	1.09e-05	8.75e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CTNNB1—uterine cancer	1.09e-05	8.71e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KRAS—uterine cancer	1.08e-05	8.65e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	1.08e-05	8.64e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKR1C3—uterine cancer	1.07e-05	8.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—KRAS—uterine cancer	1.07e-05	8.57e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—uterine cancer	1.07e-05	8.57e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—uterine cancer	1.06e-05	8.53e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.06e-05	8.5e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTEN—uterine cancer	1.06e-05	8.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—uterine cancer	1.05e-05	8.45e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.05e-05	8.43e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—uterine cancer	1.04e-05	8.37e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.04e-05	8.37e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP11A1—uterine cancer	1.04e-05	8.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SOCS3—uterine cancer	1.04e-05	8.32e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AKT1—uterine cancer	1.03e-05	8.28e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.03e-05	8.23e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTHFR—uterine cancer	1.02e-05	8.19e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PIK3CA—uterine cancer	1.02e-05	8.14e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB2—uterine cancer	1.01e-05	8.12e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EP300—uterine cancer	1.01e-05	8.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDH1—uterine cancer	9.96e-06	7.98e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RRM2—uterine cancer	9.94e-06	7.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN2B—uterine cancer	9.93e-06	7.96e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PIK3CA—uterine cancer	9.91e-06	7.94e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKR1C3—uterine cancer	9.85e-06	7.9e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB2—uterine cancer	9.83e-06	7.88e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKR1C3—uterine cancer	9.8e-06	7.86e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—DCN—uterine cancer	9.65e-06	7.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1R—uterine cancer	9.65e-06	7.73e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL8—uterine cancer	9.6e-06	7.7e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—uterine cancer	9.58e-06	7.68e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—uterine cancer	9.56e-06	7.67e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POLD1—uterine cancer	9.52e-06	7.63e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—uterine cancer	9.45e-06	7.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—uterine cancer	9.45e-06	7.57e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—uterine cancer	9.44e-06	7.57e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—uterine cancer	9.4e-06	7.53e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—uterine cancer	9.39e-06	7.53e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CDKN1B—uterine cancer	9.38e-06	7.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RRM2—uterine cancer	9.37e-06	7.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—STAR—uterine cancer	9.36e-06	7.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.36e-06	7.51e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—uterine cancer	9.3e-06	7.45e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—uterine cancer	9.22e-06	7.39e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—uterine cancer	9.17e-06	7.35e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDKN1B—uterine cancer	9.11e-06	7.3e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—DCN—uterine cancer	9.09e-06	7.29e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP11A1—uterine cancer	9.09e-06	7.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—uterine cancer	9.09e-06	7.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—uterine cancer	9.07e-06	7.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMAD3—uterine cancer	9.07e-06	7.27e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.01e-06	7.22e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKR1C1—uterine cancer	8.9e-06	7.14e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—STK11—uterine cancer	8.86e-06	7.11e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP19A1—uterine cancer	8.86e-06	7.11e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CTNNB1—uterine cancer	8.86e-06	7.1e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	8.8e-06	7.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL8—uterine cancer	8.72e-06	6.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PIK3CA—uterine cancer	8.68e-06	6.96e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.67e-06	6.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR2—uterine cancer	8.65e-06	6.94e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—uterine cancer	8.63e-06	6.92e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—uterine cancer	8.6e-06	6.9e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKR1C3—uterine cancer	8.59e-06	6.88e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP11A1—uterine cancer	8.57e-06	6.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—uterine cancer	8.4e-06	6.74e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—uterine cancer	8.38e-06	6.72e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—STK11—uterine cancer	8.37e-06	6.71e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP19A1—uterine cancer	8.37e-06	6.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—uterine cancer	8.33e-06	6.68e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—uterine cancer	8.3e-06	6.65e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EP300—uterine cancer	8.23e-06	6.6e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—uterine cancer	8.13e-06	6.52e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—uterine cancer	8.09e-06	6.49e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKR1C3—uterine cancer	8.09e-06	6.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—uterine cancer	8.03e-06	6.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—uterine cancer	8.03e-06	6.44e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EP300—uterine cancer	8e-06	6.41e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RRM2—uterine cancer	7.94e-06	6.36e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.86e-06	6.3e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—uterine cancer	7.8e-06	6.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1B—uterine cancer	7.78e-06	6.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—uterine cancer	7.76e-06	6.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—uterine cancer	7.71e-06	6.18e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DCN—uterine cancer	7.7e-06	6.18e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—uterine cancer	7.7e-06	6.17e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP19A1—uterine cancer	7.68e-06	6.16e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—STK11—uterine cancer	7.68e-06	6.16e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—STK11—uterine cancer	7.63e-06	6.12e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP19A1—uterine cancer	7.63e-06	6.12e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—EP300—uterine cancer	7.51e-06	6.02e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.5e-06	6.01e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—uterine cancer	7.48e-06	6e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—uterine cancer	7.47e-06	5.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ESR1—uterine cancer	7.4e-06	5.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—uterine cancer	7.35e-06	5.89e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POLD1—uterine cancer	7.35e-06	5.89e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP11A1—uterine cancer	7.26e-06	5.82e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—uterine cancer	7.23e-06	5.79e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.21e-06	5.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1B—uterine cancer	7.18e-06	5.76e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.17e-06	5.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—uterine cancer	7.16e-06	5.74e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—uterine cancer	7.11e-06	5.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—uterine cancer	7.09e-06	5.68e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—uterine cancer	7.02e-06	5.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—uterine cancer	7e-06	5.61e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—uterine cancer	6.91e-06	5.54e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.87e-06	5.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	6.87e-06	5.51e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKR1C3—uterine cancer	6.85e-06	5.5e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.83e-06	5.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—EP300—uterine cancer	6.83e-06	5.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—uterine cancer	6.81e-06	5.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—uterine cancer	6.79e-06	5.44e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—STK11—uterine cancer	6.69e-06	5.36e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP19A1—uterine cancer	6.69e-06	5.36e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—uterine cancer	6.66e-06	5.34e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—uterine cancer	6.63e-06	5.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—uterine cancer	6.62e-06	5.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL2—uterine cancer	6.52e-06	5.22e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—uterine cancer	6.44e-06	5.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—uterine cancer	6.39e-06	5.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—EP300—uterine cancer	6.31e-06	5.06e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—STK11—uterine cancer	6.3e-06	5.05e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP19A1—uterine cancer	6.3e-06	5.05e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—uterine cancer	6.29e-06	5.05e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RRM2—uterine cancer	6.12e-06	4.91e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—uterine cancer	6.1e-06	4.89e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—uterine cancer	6.1e-06	4.89e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	6.09e-06	4.88e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—uterine cancer	6.04e-06	4.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—uterine cancer	6.02e-06	4.83e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DCN—uterine cancer	5.95e-06	4.77e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—uterine cancer	5.92e-06	4.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—uterine cancer	5.9e-06	4.73e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—uterine cancer	5.89e-06	4.72e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—uterine cancer	5.81e-06	4.66e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—uterine cancer	5.77e-06	4.63e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—uterine cancer	5.74e-06	4.6e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—uterine cancer	5.68e-06	4.56e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	5.63e-06	4.52e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.6e-06	4.49e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—uterine cancer	5.55e-06	4.45e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.55e-06	4.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—uterine cancer	5.53e-06	4.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—uterine cancer	5.5e-06	4.41e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—uterine cancer	5.47e-06	4.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—uterine cancer	5.43e-06	4.36e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—uterine cancer	5.42e-06	4.35e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—uterine cancer	5.37e-06	4.31e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—STK11—uterine cancer	5.34e-06	4.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP19A1—uterine cancer	5.34e-06	4.28e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.29e-06	4.24e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—uterine cancer	5.17e-06	4.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—uterine cancer	5.15e-06	4.13e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—uterine cancer	5.14e-06	4.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—uterine cancer	5.12e-06	4.1e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.08e-06	4.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—uterine cancer	5.08e-06	4.07e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.06e-06	4.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—uterine cancer	5.05e-06	4.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—uterine cancer	5.03e-06	4.03e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—uterine cancer	5.03e-06	4.03e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.01e-06	4.02e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	4.97e-06	3.99e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—uterine cancer	4.93e-06	3.95e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—uterine cancer	4.83e-06	3.87e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.78e-06	3.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—uterine cancer	4.75e-06	3.81e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—uterine cancer	4.74e-06	3.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—uterine cancer	4.68e-06	3.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—uterine cancer	4.67e-06	3.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—uterine cancer	4.63e-06	3.71e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—uterine cancer	4.54e-06	3.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—uterine cancer	4.52e-06	3.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—uterine cancer	4.42e-06	3.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—uterine cancer	4.32e-06	3.46e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—uterine cancer	4.3e-06	3.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—uterine cancer	4.18e-06	3.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—uterine cancer	4.13e-06	3.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—uterine cancer	4.13e-06	3.31e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.12e-06	3.3e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—STK11—uterine cancer	4.12e-06	3.3e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—uterine cancer	4.01e-06	3.22e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—uterine cancer	4.01e-06	3.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—uterine cancer	3.81e-06	3.06e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—uterine cancer	3.71e-06	2.97e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—uterine cancer	3.65e-06	2.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—uterine cancer	3.56e-06	2.85e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.54e-06	2.83e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—uterine cancer	3.53e-06	2.83e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—uterine cancer	3.51e-06	2.82e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—uterine cancer	3.5e-06	2.81e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—uterine cancer	3.34e-06	2.68e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—uterine cancer	3.28e-06	2.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—uterine cancer	3.27e-06	2.62e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—uterine cancer	3.21e-06	2.57e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—uterine cancer	3.19e-06	2.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—uterine cancer	3.16e-06	2.53e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—uterine cancer	3.1e-06	2.48e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—uterine cancer	3.06e-06	2.45e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—uterine cancer	3.04e-06	2.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—uterine cancer	3.02e-06	2.42e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—uterine cancer	2.98e-06	2.39e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—uterine cancer	2.8e-06	2.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—uterine cancer	2.67e-06	2.14e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—uterine cancer	2.67e-06	2.14e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—uterine cancer	2.63e-06	2.11e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—uterine cancer	2.51e-06	2.01e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—uterine cancer	2.47e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—uterine cancer	2.26e-06	1.82e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—uterine cancer	2.25e-06	1.81e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—uterine cancer	2.23e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—uterine cancer	2.14e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—uterine cancer	2.13e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—uterine cancer	2.02e-06	1.62e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—uterine cancer	1.97e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.86e-06	1.49e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—uterine cancer	1.85e-06	1.48e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—uterine cancer	1.84e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—uterine cancer	1.72e-06	1.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—uterine cancer	1.64e-06	1.32e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—uterine cancer	1.61e-06	1.29e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.57e-06	1.26e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—uterine cancer	1.52e-06	1.22e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—uterine cancer	1.29e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.22e-06	9.74e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—uterine cancer	9.93e-07	7.96e-06	CbGpPWpGaD
